Name | 5-(3,3-Difluorocyclobutyl)-3-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,2,4-oxadiazole |
---|---|
Synonyms |
5-(3,3-Difluorocyclobutyl)-3-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,2,4-oxadiazole
1,2,4-Oxadiazole, 5-(3,3-difluorocyclobutyl)-3-[4-[4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl]bicyclo[2.2.2]oct-1-yl]- MK-4101 |
Description | MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma.target:SMOIn vivo: MK-4101 was highly efficacious against primary medulloblastoma and BCC developing in the cerebellum and skin of Ptch1+/- mice.In vitro: MK-4101 induce deregulation of cell cycle and block of DNA replication in tumors. MK-4101 targets the Hh pathway in tumor cells, showing the maximum inhibitory effect on Gli1. MK-4101 also induce deregulation of cell cycle and block of DNA replication in tumors. |
---|---|
Related Catalog | |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 606.1±65.0 °C at 760 mmHg |
Molecular Formula | C24H24F5N5O |
Molecular Weight | 493.472 |
Flash Point | 320.4±34.3 °C |
Exact Mass | 493.190094 |
LogP | 4.58 |
Vapour Pressure | 0.0±1.7 mmHg at 25°C |
Index of Refraction | 1.654 |
Storage condition | -20℃ |